ClinicalTrials.gg
RecruitingNCT07304076Updated Feb 25, 2026

Clinical Research on the Comparative Effectiveness and Safety of JHG002 Therapy for Chronic Low Back Pain: A Multicenter Randomized Controlled Trial

An interventional study of Hominis placental pharmacopuncture and Tanscutaneous electrical nerve stimulation (TENS) in Chronic Low Back Pain (CLBP), sponsored by Jaseng Medical Foundation. Recruiting at 4 sites in South Korea. Open to participants aged 19 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-02-25.

Sponsored by Jaseng Medical Foundation · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
19 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Low Back Pain by Jaseng Medical Foundation — 4 open to participants now, 5 under way, none of them phase 3. Low Back Pain · Jaseng Medical Foundation.

Started
2025
with 1 other
No phase
8 of 11
3 open now
Registered
10th of 11
by date

Among the 11 studies in Low Back Pain by Jaseng Medical Foundation, this one is one of 2 that started in 2025, is one of 8 with no phase, and was the 10th registered.

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

4 of the 11 studies in Low Back Pain by Jaseng Medical Foundation are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 19 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Low Back Pain by Jaseng Medical Foundation, or all of them as a file.
02

Study summary

A multicenter randomized controlled trial

Read the detailed description

This multicenter, randomized, parallel-group controlled trial aims to evaluate the effectiveness and safety of JHG002 pharmacopuncture in adults with chronic low back pain lasting more than 6 months. A total of 96 participants will be randomly assigned in a 1:1 ratio to receive either JHG002 pharmacopuncture or standard physical therapy with transcutaneous electrical nerve stimulation (TENS).

Participants in the JHG002 group will receive 10 treatment sessions over 5 weeks (twice weekly), with 0.05-0.1 mL of JHG002 administered to 8-10 acupuncture points commonly used for lumbar pain. The control group will receive standardized TENS therapy twice weekly for 15 minutes per session during the same treatment period.

Outcome assessments will be conducted at baseline and Weeks 1, 2-5, 9, 6, 13, and 25. The primary outcome is the change in low back pain intensity measured by the Numeric Rating Scale (NRS) at Week 6. Secondary outcomes include radiating leg pain NRS, visual analogue scale (VAS) scores, functional disability (Oswestry Disability Index; 6-item Roland-Morris Disability Questionnaire), quality of life (EQ-5D-5L; HINT-8), patient global impression of change (PGIC), credibility/expectancy, analgesic use, and economic outcomes such as direct/indirect medical costs and productivity loss.

Safety will be assessed through adverse event monitoring, vital signs, laboratory tests, and concomitant medication review. Adverse events will be evaluated according to WHO-UMC causality and standard severity grading. The study will follow a 4-year timeline from IRB approval to final follow-up.

03

Conditions studied

  • Chronic Low Back Pain (CLBP)

Browse trials for

Keywords

  • chronic low back pain
  • pharmacopuncture
04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 19 to 69 years at the time of signing the .
  • Individuals who have experienced low back pain for ≥6 months, presenting with either continuous or intermittent symptoms.
  • Participants with a Numeric Rating Scale (NRS) score ≥ 5 for low back pain at screening.
  • Individuals who fully understand the clinical trial procedures and voluntarily agree to participate by providing written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Patients diagnosed with serious underlying conditions that may cause low back pain, such as spinal of , acute vertebral fracture, or spinal dislocation.
  • Patients with progressive neurological deficits or those presenting with severe neurological symptoms.
  • Patients whose pain originates from non-spinal soft tissue disorders, including tumors, fibromyalgia, rheumatoid arthritis, or gout.
  • Individuals with other chronic medical conditions that may interfere with treatment response or interpretation of study outcomes, such as stroke, myocardial infarction, chronic kidney disease, diabetic neuropathy, dementia, or epilepsy.
  • Individuals currently taking , , psychiatric medications, or any other drugs that may influence study results.*
  • Patients for whom pharmacopuncture is inappropriate or unsafe, including those with bleeding disorders or those receiving anticoagulant therapy.
  • Individuals who have taken analgesic medications such as NSAIDs or received pharmacopuncture treatment within the past 1 week.
  • Women of who are unwilling to use medically acceptable (e.g., surgical sterilization, intrauterine device, condom or diaphragm use, injectable or implantable contraceptives) throughout the study period.
  • Pregnant or breastfeeding women.
  • Individuals with a history of or allergic reactions to Hominis placenta pharmacopuncture (JHG002).
  • Patients with uncontrolled diabetes mellitus (fasting blood glucose ≥ 180 mg/dL).
  • Individuals whose (GOT) or ALT (GPT) levels are ≥ 2 times the at the study site.
  • Individuals whose serum creatinine levels are ≥ 2 times the upper limit of the normal range at the study site.
  • Patients suspected of having an underlying organic disease.
  • Patients with moderate systemic complications involving organs other than the heart, liver, or kidneys.
  • Patients with psychogenic disorders.
  • Individuals with an implanted cardiac pacemaker.
  • Patients with inflammation, infection, wounds, or other lesions at the planned pharmacopuncture sites that would prevent safe administration.
  • Patients within 3 months after lumbar spine surgery.
  • Individuals who have participated in another clinical trial within the past 1 month, or who plan to participate in another clinical trial-including follow-up periods-within 6 months from the screening date.
  • Any individual deemed unsuitable for participation in this study by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
96 participants (estimated)

Study arms

  • Experimental
    Hominis placental pharmacopuncture

    Participants in the experimental group will receive JHG002 pharmacopuncture twice weekly for 5 weeks (total 10 sessions). JHG002 (0.05-0.1 mL per point) will be administered to 8-10 acupuncture points commonly used for chronic low back pain, including BL23, BL24, BL25, GV3, and GV4, with optional GB30 based on symptoms.

    Drug: Hominis placental pharmacopuncture

  • Active comparator
    Physical Therapy Group

    Participants in the control group will receive standardized transcutaneous electrical nerve stimulation (TENS) therapy twice weekly for 5 weeks (total 10 sessions). Each session will last 15 minutes and will be administered using a unified protocol across all participating sites to target the lumbar region.

    Device: Tanscutaneous electrical nerve stimulation (TENS)

Interventions

  • DrugHominis placental pharmacopuncture

    JHG002 pharmacopuncture is a purified Hominis placenta extract formulated for injection at acupuncture points. In Korean medicine, Hominis placenta has traditionally been used to support vitality, relieve chronic pain, and enhance functional recovery.

    Also known as: JHG002

  • DeviceTanscutaneous electrical nerve stimulation (TENS)

    Transcutaneous electrical nerve stimulation is a non-invasive physical therapy that delivers low-intensity electrical stimulation to the lumbar area to reduce pain and muscle tension.

    Also known as: TENS, electrical nerve stimulation

06

What researchers measure

Primary outcomes

  1. Change in low back pain intensity (NRS)

    The primary outcome is the change in low back pain intensity between baseline and Week 6. Low back pain severity during the past week will be assessed using the Numeric Rating Scale (NRS), where patients rate their pain on an 11-point scale ranging from 0 (no pain) to 10 (the worst pain imaginable). Participants will be instructed to report their average low back pain intensity over the past 7 days.

    Time frame: Week 1, 2-5, 6, 9, 13, 25

Secondary outcomes

  1. Change in radiating leg pain intensity (NRS)

    Radiating leg pain severity will be evaluated using the same 0-10 Numeric Rating Scale (NRS), assessing the degree of pain or discomfort radiating from the lumbar region to the lower extremities. Participants will indicate the level of radiating pain they experienced during the past week, with higher scores representing greater severity.

    Time frame: Week 1, 2-5, 6, 9, 13, 25

  2. Low back pain Visual Analogue Scale (VAS)

    The 100-mm Visual Analogue Scale (VAS) will be used to assess the intensity of low back pain. Participants will mark a point on a horizontal line anchored by "no pain" at the left end and "the most severe pain imaginable" at the right end. The distance in millimeters from the left end will be recorded as the pain score. This measure will be collected repeatedly to monitor pain trajectory over time.

    Time frame: Week 1, 2-5, 6, 9, 13, 25

  3. Radiating leg pain Visual Analogue Scale (VAS)

    A VAS will also be used to evaluate radiating leg pain. Participants will indicate their perceived leg pain intensity on a 100-mm line in the same format used for the low back pain VAS. This measure provides a continuous index of radiating pain severity.

    Time frame: Week 1, 2-5, 6, 9, 13, 25

  4. Oswestry Disability Index (ODI)

    The Oswestry Disability Index is a validated questionnaire assessing disability related to chronic low back pain. It consists of 10 items covering domains such as pain intensity, lifting, sitting, standing, sleep, and social life. Each item is scored from 0 to 5, and the total score is converted into a percentage (0-100%), with higher scores indicating greater functional impairment.

    Time frame: Weeks 1, 6, 13, 25

  5. 6-item Roland-Morris Disability Questionnaire (RMDQ-6)

    The RMDQ-6 is a short form of the Roland-Morris Disability Questionnaire that evaluates functional limitations in daily activities due to low back pain. The questionnaire consists of 6 binary (yes/no) items, and the total score ranges from 0 to 6. Higher scores reflect more severe disability.

    Time frame: Weeks 1, 6, 13, 25

  6. Patient Global Impression of Change (PGIC)

    PGIC is a single-item global assessment that measures the participant's overall perception of improvement or worsening after treatment. It uses a 7-point Likert scale, ranging from "very much improved" to "very much worse." This outcome captures the participant's subjective treatment benefit.

    Time frame: Week 6, 13, 25

  7. Health-related Quality of Life (EQ-5D-5L)

    The EQ-5D-5L evaluates quality of life across five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each item has five response levels (no problems to extreme problems). The questionnaire also includes a 0-100 visual analogue scale to assess the participant's self-rated health status. Higher index values and VAS scores indicate better quality of life.

    Time frame: Weeks 1, 6, 13, 25

  8. HINT-8 (Health-related Quality of Life Instrument)

    HINT-8 is a Korean-developed quality-of-life measurement tool consisting of eight items assessing physical, social, and mental health. Each item uses a 4-level response scale, and lower scores indicate better health status. This instrument is widely used in Korean health-economic studies.

    Time frame: Weeks 1, 6, 13, 25

  9. Analgesic consumption

    Participants will record all use of rescue analgesic medications throughout the study period. Data will include type, dose, frequency, and duration of use. Increased analgesic intake may indicate worsening symptoms or insufficient treatment response.

    Time frame: Week 1, 2-5, 6, 9, 13, 25

  10. Credibility and Expectancy Questionnaire

    This scale evaluates the participant's belief in the credibility and potential effectiveness of the assigned treatment. It includes both cognitive credibility items and emotional expectancy items, scored on Likert scales. Higher scores indicate greater perceived treatment plausibility and expected benefit.

    Time frame: Screening

  11. Work Productivity and Activity Impairment Questionnaire (WPAI)

    The WPAI assesses the impact of low back pain on work performance and daily activities. It includes four domains: absenteeism, presenteeism, overall work impairment, and activity limitations. Scores are expressed as percentages, with higher percentages reflecting greater impairment.

    Time frame: Week 1, 2-5, 6, 9, 13, 25

  12. Economic evaluation variables

    Costs related to medical care, transportation, time burden, lost productivity, and indirect cost components will be collected to evaluate the cost-effectiveness of JHG002 compared with TENS. Data will be used for both cost-effectiveness and cost-utility analyses.

    Time frame: Week 2

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Nov 2029, 47 months after the start.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's planned 47 months is above that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2025
First posted
Dec 26, 2025
StartActual
Dec 17, 2025
Primary completionEst.
Nov 28, 2029
CompletionEst.
Nov 28, 2029
Last update
Feb 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07304076
Lead sponsor
Jaseng Medical Foundation
Responsible party
Sponsor
First posted
Dec 26, 2025
Start date
Dec 17, 2025
Primary completion
Nov 28, 2029 (estimated)
Completion
Nov 28, 2029 (estimated)
Last update
Feb 25, 2026

Study contacts

In-Hyuk Ha, Dr
Contact
hanihata@gmail.com
+82-1577-0007

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion